Edition:
United States

Bristol-Myers Squibb Co (BMY.N)

BMY.N on New York Stock Exchange

62.41USD
15 Dec 2017
Change (% chg)

$0.28 (+0.45%)
Prev Close
$62.13
Open
$62.49
Day's High
$62.83
Day's Low
$61.98
Volume
4,235,808
Avg. Vol
1,511,689
52-wk High
$66.09
52-wk Low
$46.01

Select another date:

Wed, Dec 13 2017

BRIEF-Ono Pharmaceutical enters into license agreement with Bristol-Myers Squibb for Prostaglandin E2 receptor antagonists

* Says it entered into license agreement with Bristol-Myers Squibb Company (BMS)for Prostaglandin E2 receptor antagonists relating to Immuno-Oncology programs

BRIEF-Bristol-Myers Squibb Granted Exclusive License By Ono Pharmaceutical For Multiple Programs Targeting Immuno-Suppressive Factors In The Tumor Microenvironment

* BRISTOL-MYERS SQUIBB GRANTED EXCLUSIVE LICENSE BY ONO PHARMACEUTICAL FOR MULTIPLE PROGRAMS TARGETING IMMUNO-SUPPRESSIVE FACTORS IN THE TUMOR MICROENVIRONMENT

BRIEF-U.S. FDA Accepts Bristol-Myers Squibb’S Application For Opdivo (Nivolumab) Plus Yervoy (Ipilimumab)

* U.S. FOOD AND DRUG ADMINISTRATION (FDA) ACCEPTS BRISTOL-MYERS SQUIBB’S APPLICATION FOR OPDIVO (NIVOLUMAB) PLUS YERVOY (IPILIMUMAB) IN INTERMEDIATE- AND POOR-RISK PATIENTS WITH ADVANCED RENAL CELL CARCINOMA AND GRANTS PRIORITY REVIEW

BRIEF-Bristol-Myers Squibb Announces 2.6 Pct Increase In Quarterly Dividend Beginning Q1 2018

* BRISTOL-MYERS SQUIBB CO - AN INCREASE OF 2.6% PERCENT IN COMPANY'S QUARTERLY DIVIDEND, BEGINNING IN Q1 OF 2018

BRIEF-Ayala Enters Exclusive Worldwide License Agreement With Bristol-Myers Squibb

* AYALA PHARMACEUTICALS, FOUNDED BY ISRAEL BIOTECH FUND, AMOON AND HAREL INSURANCE, ENTERS EXCLUSIVE WORLDWIDE LICENSE AGREEMENT WITH BRISTOL-MYERS SQUIBB (BMS) TO DEVELOP CANCER TREATMENTS

BRIEF-European Medicines Agency Validates Bristol-Myers's Type II Variation Application For Opdivo

* EUROPEAN MEDICINES AGENCY VALIDATES BRISTOL-MYERS SQUIBB’S TYPE II VARIATION APPLICATION FOR OPDIVO (NIVOLUMAB) PLUS YERVOY (IPILIMUMAB) IN INTERMEDIATE- AND POOR-RISK PATIENTS WITH ADVANCED RENAL CELL CARCINOMA Source text for Eikon: Further company coverage:

BRIEF-Bristol-Myers and Syngene expand ongoing research collaboration

* Bristol-Myers Squibb and Syngene International expand ongoing research collaboration

BRIEF-Syngene International ‍expands collaboration with Bristol-Myers Squibb​

* Nnext phase of partnership will see addition of facility to support future Bristol-Myers Squibb research and development operations​ Source text: http://bit.ly/2iT2tvz Further company coverage:

BRIEF-Bristol-Myers says encouraging response observed with Opdivo plus BMS-986205, in heavily pre-treated patients with advanced cancers in early-stage study

* Encouraging response observed with Opdivo (nivolumab) plus investigational ido1 inhibitor, BMS-986205, in heavily pre-treated patients with advanced cancers in phase 1/2a study ca017-003

Select another date: